RBBP6 maintains glioblastoma stem cells through CPSF3-dependent alternative polyadenylation

Peng Lin,Wenyan Chen,Zhilin Long,Jichuan Yu,Jiayao Yang,Zhen Xia,Qiulian Wu,Xinyu Min,Jing Tang,Ya Cui,Fuyi Liu,Chun Wang,Jian Zheng,Wei Li,Jeremy N. Rich,Lei Li,Qi Xie

DOI: https://doi.org/10.1038/s41421-024-00654-3

IF: 38.079

2024-03-20

Cell Discovery

Abstract:Glioblastoma is one of the most lethal malignant cancers, displaying striking intratumor heterogeneity, with glioblastoma stem cells (GSCs) contributing to tumorigenesis and therapeutic resistance. Pharmacologic modulators of ubiquitin ligases and deubiquitinases are under development for cancer and other diseases. Here, we performed parallel in vitro and in vivo CRISPR/Cas9 knockout screens targeting human ubiquitin E3 ligases and deubiquitinases, revealing the E3 ligase RBBP6 as an essential factor for GSC maintenance. Targeting RBBP6 inhibited GSC proliferation and tumor initiation. Mechanistically, RBBP6 mediated K63-linked ubiquitination of Cleavage and Polyadenylation Specific Factor 3 (CPSF3), which stabilized CPSF3 to regulate alternative polyadenylation events. RBBP6 depletion induced shortening of the 3'UTRs of MYC competing-endogenous RNAs to release miR-590-3p from shortened UTRs, thereby decreasing MYC expression. Targeting CPSF3 with a small molecular inhibitor (JTE-607) reduces GSC viability and inhibits in vivo tumor growth. Collectively, RBBP6 maintains high MYC expression in GSCs through regulation of CPSF3-dependent alternative polyadenylation, providing a potential therapeutic paradigm for glioblastoma.

cell biology